‘Old' and ‘new' drugs for the treatment of cancer pain

Bibliography

• Ripamonti CI, Bandolieri E, Roila F. Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol 2011; 22(Suppl 6): vi69-77
   Google Scholar
• World Health Organization. Cancer pain relief. World Health Organization; Geneva: 1986
   Google Scholar
• Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA 1995;274:1870-3
   PubMed Web of Science ®Google Scholar
• Caraceni A, Hanks G, Kaasa S, European Palliative Care Research Collaborativ (EPCRC); European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13(2):e58-68
   PubMed Web of Science ®Google Scholar
• Ripamonti C, Santini D, Maranzano E, ESMO Guidelines Working Group. Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol 2012;23(Suppl 7):vii139-54
   PubMed Web of Science ®Google Scholar
• McNicol E, Strassels S, Gouds L, NSAIDs or paracetamol, alone or combined with opioids, for cancer pain (cochrane review). John Wiley & Sons, Ltd; In the Cochrane Library Issue 1 2009
   Google Scholar
• Eisenberg E, Berkey C, Carr DB, Efficacy and safety of nonsteroidal antinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 1994;12:2756-65
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality. Evidence report/technology assessment: number 35. 2001
   Google Scholar
• Grond S, Radbruch L. Weak opioids. Meta-analysis for the therapy of chronic pain. Schmerz 1998;12:142-55
   PubMed Web of Science ®Google Scholar
• Arbaiza D, Vidal O. Tramadol in the treatment of neuropathic cancer pain: a double-blind, placebo-controlled study. Clin Drug Investig 2007;27(1):75-83
   PubMed Web of Science ®Google Scholar
• Rodriguez RF, Castillo JM, Castillo MP, Hydrocodone/acetaminophen and tramadol chloridrate combination tablets for the management of chronic cancer pain: a doubl-blind comparative trial. Clin J Pain 2008;24(1):1-4
   PubMed Web of Science ®Google Scholar
• Rodriguez RF, Bravo LE, Castro F, Incidence of weak opioids adverse events in the management of cancer pain: a double-blind comparative trial. J Palliat Med 2007;10:56-60
   PubMed Web of Science ®Google Scholar
• De Conno F, Ripamonti C, Sbanotto A, A clinical study on the use of codeine, oxycodone, dextropropoxyphene, buprenorphine, and pentazocine in cancer pain. J Pain Symptom Manage 1991;6:423-7
   PubMed Web of Science ®Google Scholar
• Ventafridda V. A validation study of the WHO method for cancer pain relief. Cancer 1987;59:851-6
   Web of Science ®Google Scholar
• Marinangeli F, Ciccozzi A, Leonardis M, Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage 2004;27:409-16
   PubMed Web of Science ®Google Scholar
• Mercadante S, Porzio G, Ferrera P, Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage 2006;31:242-7
   PubMed Web of Science ®Google Scholar
• Tassinari D, Drudi F, Rosati M, The second step of the analgesic ladder and oral tramadol in the treatment of mild to moderate cancer pain: a systematic review. Palliat Med 2011;25(5):410-23
   PubMed Web of Science ®Google Scholar
• Greco MT, Corli O, Montanari M, Epidemiology and pattern of care of Breakthrough cancer pain in a longitudinal sample of cancer patients. Results from the cancer pain outcome research and study group. Clin J Pain 2011;27:9-18
   PubMed Web of Science ®Google Scholar
• Mercadante S, Villari P, Ferrera P, Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer 2007;12:1828-33
   Web of Science ®Google Scholar
• Mercadante S, Radbruch I, Caraceni A, Episodic breakthrough pain: consensus conference of an export working group of the European Association for Palliative Care. Cancer 2002;94:832-9
   PubMed Web of Science ®Google Scholar
• Zeppetella G, Riberio MDC. Opioids for the management of breakthrough episodic pain in cancer patients. Cochrane Database Systematic Rev 2006;1:CDOO4311
   Google Scholar
• Portenoy RK, Burton AW, Gabrail N, Taylor D; Fentanyl Pectin Nasal Spray 043 Study Group. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain 2010;151:617-24
   PubMed Web of Science ®Google Scholar
• Christie JM, Simmonds M, Patt R, Dose titration: a multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998;16:3238-45
   PubMed Web of Science ®Google Scholar
• Farrar JT, Clearly J, Rauck R, Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998;90(8):611-16
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Payne R, Coluzzi P, Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999;79:303-12
   PubMed Web of Science ®Google Scholar
• Coluzzi PH, Schwartzberg L, Conroy JD, Breakthrough cancer pain: a randomized trial comparing oral transmucosal fen tanyl citrate (OTFC) and morphine sulphate immediate release (MSIR). Pain 2001;91:123-30
   PubMed Web of Science ®Google Scholar
• Uberall MA, Muller-Schwefe Gerhard HH. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain. Curr Med Res Opin 2011;27(7):1385-94
   PubMed Web of Science ®Google Scholar
• Ripamonti C, Bareggi C. Pharmacology of opioid analgesia: clinical principles. In: Bruera E, Portenoy R, editors, Cancer pain. Assessment and management. Cambridge University Press, 2010. p. 195-229
   Google Scholar
• Vissers D, Stam W, Nolte T, Efficacy of intranasal fentanyl spray vs other opioids for breakthrough pain in cancer. Curr Med Res Opin 2010;26:1037-45
   PubMed Web of Science ®Google Scholar
• Mistakydou K, Panagiotou I, Gouliamos A. Fentanyl nasal spray for the treatment of cancer pain. Expert Opin Pharmacother 2011;12(10):1953-9
   Web of Science ®Google Scholar
• Mercadante S, Radbruch L, Davies AN, A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain- an open label, randomized, cross-over trial. Curr Med Res Opin 2009;25(11):2805-15
   PubMed Web of Science ®Google Scholar
• Davies A, Sitte T, Elsner F, Consistency of efficaccy, patient Accettability and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulphate in breakthrough cancer pain. J pain Symptom Manage 2011;41:358-66
   PubMed Web of Science ®Google Scholar
• Ventafridda V, Ripamonti C, Bianchi M, A randomized study on oral administration of morphine and methadone in the treatment of cancer pain. J Pain Symptom Manage 1986;1:203-7
   PubMedGoogle Scholar
• Cherny N. Is oral methadone better than placebo or other oral/transdermal opioids in the management of pain? Palliat Med 2011;25:488-93
   PubMed Web of Science ®Google Scholar
• Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. J Palliat Med 2002;5(1):127-38
   PubMedGoogle Scholar
• Fitzgibbon DR, Ready LB. Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine. Pain 1997;73:259-61
   PubMed Web of Science ®Google Scholar
• Santiago-Palma J, Khojainova N, Kornick C, Intravenous methadone in the management of chronic cancer pain. Safe and effective starting doses when substituting methadone for fentanyl. Cancer 2001;92:1919-25
   PubMed Web of Science ®Google Scholar
• Caraceni A, Hanks G, Kaasa S, Use of opioid anakgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13:e58-68
   PubMed Web of Science ®Google Scholar
• Gorman AL, Elliott KJ, Inturrisi CE, The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-d-aspartate receptor in rat forebrain and spinal cord. Neurosci Lett 1997;223:5-8
   PubMed Web of Science ®Google Scholar
• Egbert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-d-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett 1995;187:165-8
   PubMed Web of Science ®Google Scholar
• Bruera E, Watanabe S, Faisinger RL, Custom-made capsules and suppositories of methadone for patients on high- dose opioids for cancer pain. Pain 1995;62:141-6
   PubMed Web of Science ®Google Scholar
• Moryl N, Kogan M, Comfort C, Obbens E. Methadone in the treatment of pain and terminal delirum in advanced cancer patients. Palliat Support Care 2005;3(4):311-17
   PubMedGoogle Scholar
• Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain 1997;70:109-15
   PubMed Web of Science ®Google Scholar
• Ripamonti C, Maniezzo M, Campa T, Decreased occurrence of osteonecrosis of the jaws (ONJs) after implementation of dental preventive measure in solid tumors treated with bisphosphonates. The experience of the National Cancer Institute of Milan, Italy. Ann Oncol 2009;20:137-45
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Bamia C, Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009;20:117-20
   PubMed Web of Science ®Google Scholar
• Stopeck A, Lipton A, Body JJ, Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28(35):5132-9
   PubMed Web of Science ®Google Scholar
• Henry DH, Costa L, Goldwasser F, Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29(9):1125-32
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377(9768):813-22
   PubMed Web of Science ®Google Scholar
• Cleeland CS, Pain outcomes in a randomized phase 3 clinical trial on Denosumab vs Zoledronic Acid (ZA) in patients with solid tumors and bone metastases. Ann Oncol 2010;21(8s):abstract 1248P
   Google Scholar
• Van Poznak CH, Temin S, Yee GC, American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone modifying agents in metastatic breast cancer. J Clin Oncol 2011;29(9):1221-7
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, De Bono S, Molina A, Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): results from the COU-AA-301 phase III study. J Clin Oncol 2011;29(Suppl):abstract 4520
   Google Scholar
• Ripamonti CI, Santini D, Maranzano E, ESMO Guidelines Working Group. Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol 2012;23(Suppl 7):vii139-54
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cancer pain relief. 2nd edition. World Health Organization; Geneva: 1996
   Google Scholar
• Weinberg DS, Inturrisi CE, Reidewberg B, Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988;44:335-42
   PubMed Web of Science ®Google Scholar
• Payne R, Coluzzi P, Hart L, Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage 2001;22:575-83
   PubMed Web of Science ®Google Scholar
• Mercandante S, Casuccio A, Agnello A, Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. J Clin Oncol 1998;16(11):3656-61
   PubMed Web of Science ®Google Scholar
• Fainsinger R, Schoeller T, Bruera E. Methadone in the management of cancer pain: a review. Pain 1993;52:137-47
   PubMed Web of Science ®Google Scholar
• Mercadante S, Casuccio A, Agnello A, Barresi L. Methadone response in advanced cancer patients with pain followed at home. J Pain Symptom Manage 1999;18:188-92
   PubMed Web of Science ®Google Scholar
• Wheeler WL, Dickerson ED. Clinical application of methadone. Am J Hosp Palliat Care 2000;17(3):1-8
   Google Scholar
• Bruera E, Pereira J, Watanabe S, Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996;78:852-7
   PubMed Web of Science ®Google Scholar
• Ripamonti C, Groff L, Brunelli C, Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 1998;16(10):3216-21
   PubMed Web of Science ®Google Scholar
• Davis MP, Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocol of administration. Support Care Cancer 2001;9:73-83
   PubMed Web of Science ®Google Scholar
• Bryson J, Tamber A, Seccareccia D, Zimmermann C. Methadone for treatment of cancer pain. Curr Oncol Rep 2006;8(4):282-8
   PubMedGoogle Scholar
• Morley JS, Makin MK. The use of methadone in cancer pain poorly responsive to other opioids. Pain Rev 1998;5:51-8
   Web of Science ®Google Scholar
• Crews JC, Sweeney NJ, Denson DD. Clinical efficacy of methadone in patients refractory to other mu-opioid receotor agonist analgesics for management of terminal cancer pain. Cancer 1993;72:2266-72
   PubMed Web of Science ®Google Scholar
• Ripamonti C, Zecca E, Brunelli C, Rectal methadone in cancer patients with pain. A preliminary clinical and pharmacokinetic study. Ann Oncol 1995;6:841-3
   PubMed Web of Science ®Google Scholar